ESTRO 2024 - Abstract Book

S2619

Clinical - Urology

ESTRO 2024

3145

Digital Poster

The role of metastasis directed therapy in the oligometastic prostate cancer patient journey

Federico Mastroleo 1,2 , Riccardo Villa 1,3 , Lorenzo Colombi 1,3 , Ekaterina Milovanova 1,3 , Constantinos Zamboglou 4,5 , Francesco Ceci 6,3 , Giuseppe Petralia 7,3 , Maria Giulia Vincini 1 , Mattia Zaffaroni 1 , Giulia Marvaso 1,3 , Pierfrancesco Franco 2 , Barbara Alicja Jereczek-Fossa 1,3 1 IEO European Institute of Oncology IRCCS, Division of Radiation Oncology, Milan, Italy. 2 University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy. 3 University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy. 4 University Hospital Freiburg, Department of Radiotherapy, Freiburg, Germany. 5 German Oncology Center, Division of Radiation Oncology, Limassol, Cyprus. 6 IEO European Institute of Oncology IRCCS, Division of Nuclear Medicine, Milan, Italy. 7 IEO European Institute of Oncology IRCCS, Division of Radiology, Milan, Italy

Purpose/Objective:

Recent years have witnessed a rising interest in oligometastatic hormone-sensitive prostate cancer (omHSPCa) and the relevant role of metastasis-directed therapy (MDT) using SBRT. Despite advancements in tailored treatments, the heterogeneity within the omHSPCa patient group remains a challenge. This research aims to evaluate the trajectories of metachronous omHSPCa patients, focusing on the influence of various clinical factors on the oncological outcomes - Clinical Progression Free Survival (CPFS) after first MDT treatment, Castration Resistance Free Survival (CRFS) and Free Survival to Polimetastatic state (PMFS)

Material/Methods:

The study included patients diagnosed with metachronous omHSPCa, having ≤ 5 metastases, who underwent MDT by SBRT from 2014 to 2022 at the European Institute of Oncology, Milan, Italy. Kruskal-Wallis test was used to compare medians in the distributions. Kaplan-Meier survival curves were plot and log-rank was used to ascertain significative differences. Univariate Cox regression analyses was carried out and significant features were included in the multivariate Cox regression. Process mining analysis was performed using the pMineR and pMinShiny libraries. All analyses were conducted using R and RStudio.

Results:

The study included 248 patients with a median age at primary diagnosis of 64 [IQR 58-68]. Median follow-up was 8.0 years [IQR 5.3-11.9] and the median time to first clinical recurrence from the treatment of the primary tumor was 4.24 years [IQR 2.18 – 7.44].